Study explores role of immune cells in cancer treatment outcomes

A groundbreaking study from University College London has uncovered critical insights into how immune cells impact cancer treatment outcomes. Researchers developed an innovative technique called ImmuneLENS that examines genome sequencing to evaluate immune cell proportions in patients. The research revealed that higher T cell levels in blood are associated with significantly improved survival rates, potentially offering a new diagnostic approach for clinicians. These findings could revolutionize cancer prognosis and treatment strategies by providing more precise predictive markers.

"May be able to predict how long a cancer patient will survive better than the number of T cells in the tumour alone" - Prof. Nicholas McGranahan, UCL Cancer Institute

The immune systems of cancer patients may play a significant role in their treatment outcomes, according to a study on Tuesday.

Key Points

1 Pioneering ImmuneLENS technique analyzes genome sequencing data

2 T cell proportion strongly predicts cancer outcomes

3 Male cancer patients show faster immune cell decline

4 Potential early cancer detection through blood immune markers

In the study, researchers at the University College London and the Francis Crick Institute found that cancer patients with a higher number of immune cells in their blood have a better survival rate.

They used a pioneering technique -- Immune Lymphocyte Estimation from Nucleotide Sequencing (ImmuneLENS), which enables researchers to calculate the proportion of T cells and B cells (types of immune cells) from whole genome sequencing (WGS) data.

The team analysed over 90,000 WGS samples -- both of healthy individuals and cancer patients. The findings described in the journal Nature Genetics showed that cancer patients had a lower proportion of T cells circulating in the blood compared to healthy individuals.

Further, T cell proportion was found to be a strong predictor of cancer outcomes, with higher proportions associated with 47 per cent fewer deaths over five years after surgery.

This effect was still significant when accounting for age, cancer stage, and across all cancer types -- biological markers which can be added to current genetic diagnostic tests to help clinicians with more information on which to base treatment plans, said the researchers.

Professor Nicholas McGranahan, senior author of the study from UCL Cancer Institute, said while most immune system analysis until now has focused on the tumour itself, with the new tool, doctors "may be able to predict how long a cancer patient will survive better than the number of T cells in the tumour alone".

The study also showed that in people with cancer, particularly males, the proportion of immune cells in the blood diminishes faster. However, the reason behind these sexual differences remains unclear.

They also observed that individuals who were seemingly healthy at the time their sample was taken for sequencing, who subsequently went on to develop cancer, had below-average levels of B cells in their blood.

This could be because of undiagnosed early-stage cancer, or pre-cancerous changes to the immune system that could potentially have been an early sign of disease or even a factor in cancer development.

This information could be used in the future for cancer early detection or to help clinicians understand how the patient may respond to treatment, said the researchers.

https://www.newkerala.com/news/o/study-explores-role-immune-cells-cancer-treatment-outcomes-673